Description

Composition: Vildagliptin 50 mg + Metformin 500 mg Tablet
Therapeutic Category: Anti-Diabetic Combination (DPP-4 Inhibitor + Biguanide)

Medvilda M50 offers comprehensive diabetes control through a synergistic combination of Vildagliptin and Metformin. While Vildagliptin improves pancreatic insulin response and balances glucagon, Metformin reduces liver glucose output and enhances insulin sensitivity in muscles.
Together, they provide rapid HbA1c improvement, improved glycemic stability, and long-term cardiovascular safety for patients with Type 2 Diabetes Mellitus.

Key Benefits:

• Dual mechanism for stronger sugar control
• Targets both insulin secretion and glucose production
• Supports weight stability and metabolic health
• Safe and effective for long-term therapy